GlassScriptPhysician profile
Nabil Hilwa
NPI 1023041332
$792.47
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $777 · 2020: $15.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $204.86 | 2019 | |
| Acell, INC. | $124.99 | 2019 | |
| Janssen Biotech, INC. | $108.41 | 2019 | |
| Boston Scientific Corporation | $60.03 | 2019 | |
| Pfizer INC. | $56.31 | 2019 | |
| Allergan, INC. | $50.13 | 2019 | |
| Coloplast Corp | $44.51 | 2019 | |
| Endo Pharmaceuticals INC. | $43.92 | 2019 | |
| Dentsply Ih INC. | $41.89 | 2019-2020 | |
| Therapeuticsmd, INC. | $31.24 | 2019 | |
| 180 Medical, INC. | $14.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabil Hilwa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.